{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:12:33Z","timestamp":1788599553637,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["BSR-SRF"],"award-info":[{"award-number":["BSR-SRF"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bmc.2026.118764","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:30:50Z","timestamp":1786033850000},"page":"118764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel furo[2,3-d]pyrimidinones as direct thrombin inhibitors: Design, synthesis and biological evaluation"],"prefix":"10.1016","volume":"142","author":[{"given":"Atul N.","family":"Khadse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik H.","family":"Savsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh V.","family":"Chikhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant V.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant R.","family":"Murumkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana J.","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mange Ram","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmc.2026.118764_bb0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/acscentsci.5c01473","article-title":"From prompt to drug: toward pharmaceutical superintelligence","volume":"12","author":"Zhavoronkov","year":"2026","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmc.2026.118764_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.bmc.2026.118764_bb0015","doi-asserted-by":"crossref","first-page":"24830","DOI":"10.1021\/acs.jmedchem.5c02894","article-title":"Fragment-to-Lead medicinal chemistry publications in 2024: a tenth annual perspective","volume":"68","author":"Twigg","year":"2025","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118764_bb0020","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site","volume":"64","author":"Xu","year":"2021","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118764_bb0025","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.bmcl.2019.04.009","article-title":"Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy","volume":"29","author":"Wang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmc.2026.118764_bb0030","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","article-title":"Discovery of novel Aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung Cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114860","article-title":"Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors","volume":"245","author":"Zhou","year":"2023","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmc.2026.118764_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140125","article-title":"Discovery of novel thiophene [2,3-D] pyrimidine\u2013thiazole derivative as promising MNK inhibitor to treat breast cancer","volume":"1321","author":"Zhu","year":"2025","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118764_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118764_bb0050","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114846","article-title":"The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance","volume":"244","author":"Ye","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0060","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1039\/D2SC06860E","article-title":"Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold","volume":"14","author":"Liu","year":"2023","journal-title":"Chem Sci"},{"issue":"4","key":"10.1016\/j.bmc.2026.118764_bb0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bmcl.2018.12.065","article-title":"Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes","volume":"29","author":"He","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2026.118764_bb0070","doi-asserted-by":"crossref","first-page":"14862","DOI":"10.1038\/s41598-017-13868-1","article-title":"Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118764_bb0075","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1002\/anie.201004575","article-title":"Oral, direct thrombin and factor xa inhibitors: the replacement for warfarin, leeches and pig intestine?","volume":"50","author":"Straub","year":"2011","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2026.118764_bb0080","doi-asserted-by":"crossref","first-page":"8696","DOI":"10.1021\/jm401169a","article-title":"Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl) pyridine at the P1 position with potent coagulant activity","volume":"56","author":"de Candia","year":"2013","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118764_bb0085","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/med.21503","article-title":"Recent advances in the discovery and development of factor XI\/XIa inhibitors","volume":"38","author":"Al-Horani","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118764_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112878","article-title":"From ancient leech to direct thrombin inhibitors and beyond: new from old","volume":"149","author":"Montinari","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"10264","key":"10.1016\/j.bmc.2026.118764_bb0095","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bmc.2026.118764_bb0100","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.clinthera.2021.09.021","article-title":"Real-world anticoagulant use and incidence of venous thromboembolism and major bleeding in children","volume":"43","author":"Hardin","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmc.2026.118764_bb0105","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2174\/1389557518666180424120726","article-title":"Advances in the development of novel factor xa inhibitors: a patent review","volume":"18","author":"Khadse","year":"2018","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0110","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1016\/j.bmcl.2011.07.023","article-title":"Synthesis and biological evaluation of triazole\/tetrazole-containing sulfonamides against thrombin and related serine proteases","volume":"21","author":"Siles","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/med.20016","article-title":"Progress in the design of low molecular weight thrombin inhibitors","volume":"25","author":"Srivastava","year":"2005","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118764_bb0120","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.bmc.2016.04.038","article-title":"Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues","volume":"24","author":"Wang","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0125","series-title":"Vascular Medicine: A Companion to Braunwald\u2019s Heart Disease","first-page":"94","article-title":"Pharmacology of antithrombotic drugs","author":"Haqqani","year":"2013"},{"key":"10.1016\/j.bmc.2026.118764_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ardp.201400463","article-title":"Synthesis and biological evaluation of some new 2,5-substituted 1-ethyl-1H-benzoimidazole fluorinated derivatives as direct thrombin inhibitors","volume":"348","author":"Li","year":"2015","journal-title":"Arch Pharm Chem Life Sci"},{"key":"10.1016\/j.bmc.2026.118764_bb0135","doi-asserted-by":"crossref","first-page":"11046","DOI":"10.3390\/molecules200611046","article-title":"Development of orally active thrombin inhibitors for the treatment of thrombotic disorder diseases","volume":"20","author":"He","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118764_bb0140","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1021\/acs.jmedchem.0c01035","article-title":"Design, synthesis, and pharmacological characterization of a neutral, non-prodrug thrombin inhibitor with good Oral pharmacokinetics","volume":"63","author":"Hillisch","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/13543776.2014.845169","article-title":"An update on recent patents on thrombin inhibitors (2010\u22122013)","volume":"24","author":"Mehta","year":"2014","journal-title":"Exp Opin Ther Pat"},{"issue":"17","key":"10.1016\/j.bmc.2026.118764_bb0150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/17460441.2016.1188077","article-title":"The discovery of dabigatran etexilate for the treatment of venous thrombosis","volume":"11","author":"Feuring","year":"2016","journal-title":"Exp Opin Drug Disc"},{"key":"10.1016\/j.bmc.2026.118764_bb0155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11164-015-2053-y","article-title":"Synthesis and biological evaluation of novel dabigatran derivatives as thrombin inhibitors","volume":"42","author":"Li","year":"2016","journal-title":"Res Chem Intermed"},{"key":"10.1016\/j.bmc.2026.118764_bb0160","doi-asserted-by":"crossref","first-page":"23737","DOI":"10.1039\/C5RA01828E","article-title":"Design, synthesis, biological evaluation and molecular docking of novel dabigatran derivatives as potential thrombin inhibitors","volume":"5","author":"Li","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2026.118764_bb0165","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejmech.2016.12.015","article-title":"Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: design, synthesis and anticoagulant activity evaluation","volume":"126","author":"Yang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0170","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0960-894X(00)00211-0","article-title":"Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. Part 6: further focus on the contracted C4\u2032-side chain analogues","volume":"10","author":"Takeuchi","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2012.01.059","article-title":"Fluorinated dual antithrombotic compounds based on 1,4- benzoxazine scaffold","volume":"50","author":"Ilic","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0180","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1021\/jm400369q","article-title":"Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition","volume":"56","author":"Sidhu","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0185","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1021\/jm901802n","article-title":"Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif","volume":"53","author":"Lu","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0190","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm980368v","article-title":"Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates","volume":"41","author":"Sanderson","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0195","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10867-013-9299-7","article-title":"Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A2: insight from molecular docking studies","volume":"39","author":"Yadava","year":"2013","journal-title":"J Biol Phys"},{"key":"10.1016\/j.bmc.2026.118764_bb0200","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/S0960-894X(03)00442-6","article-title":"Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives","volume":"13","author":"Ries","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/S0960-894X(03)00443-8","article-title":"Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents","volume":"13","author":"Ries","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.bmc.2026.118764_bb0210","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1021\/acs.jmedchem.2c01434","article-title":"Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118764_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126751","article-title":"Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent notum inhibitors","volume":"30","author":"Atkinson","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"10.1016\/j.bmc.2026.118764_bb0220","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1016\/j.bmcl.2016.09.077","article-title":"Synthesis and optimization of Furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors","volume":"26","author":"Hoemann","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114646","article-title":"Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A","volume":"242","author":"Yu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bmcl.2014.12.039","article-title":"Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents","volume":"25","author":"Yang","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133974","article-title":"Design, synthesis and biological evaluation of piperazinylanthranilamides as potential factor xa inhibitors","volume":"1270","author":"Khadse","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118764_bb0240","first-page":"802","article-title":"2-aminobenzamide-based factor xa inhibitors with novel mono-and bi-aryls as S4 binding elements","volume":"4","author":"Patel","year":"2019","journal-title":"Chem Select"},{"issue":"5","key":"10.1016\/j.bmc.2026.118764_bb0245","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3109\/14756366.2015.1060480","article-title":"Design, green synthesis and pharmacological evaluation of novel 5,6-diaryl-1,2,4-triazines bearing 3-morpholinoethylamine moiety as potential antithrombotic agents","volume":"31","author":"Tamboli","year":"2016","journal-title":"J Enz Inh Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0250","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/ci200185q","article-title":"Profiling the structural determinants for the selectivity of representative factor-xa and thrombin inhibitors using combined ligand-based and structure-based approaches","volume":"51","author":"Bhunia","year":"2011","journal-title":"J Chem Inf Mod"},{"key":"10.1016\/j.bmc.2026.118764_bb0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3998\/ark.5550190.0009.d18","article-title":"Efficient synthesis of furo[2,3-d]pyrimidin-4(3H)-ones","volume":"xiii","author":"Hu","year":"2008","journal-title":"ARKIVOC"},{"issue":"2","key":"10.1016\/j.bmc.2026.118764_bb0260","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jhet.30","article-title":"A novel microwave-assisted green synthesis of condensed 2-substituted-pyrimidin-4(3H)-ones under solvent-free conditions","volume":"46","author":"Jain","year":"2009","journal-title":"J Heterocycl Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0265","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1016\/S0040-4039(01)83457-2","article-title":"Weinreb SMA mild, general method for conversion of esters to amides","volume":"48","author":"Basha","year":"1977","journal-title":"Tetrahedr Lett"},{"key":"10.1016\/j.bmc.2026.118764_bb0270","series-title":"Design and Synthesis of some Novel Heterocyclic Compounds as Potential Antithrombotic Agents","author":"Khadse","year":"2021"},{"key":"10.1016\/j.bmc.2026.118764_bb0275","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/molecules22101588","article-title":"Novel FXa inhibitor identification through integration of ligand- and structure-based approaches","volume":"22","author":"Lagos","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118764_bb0280","article-title":"Novel anthranilamide-based FXa inhibitors: drug design, synthesis and biological evaluation","volume":"21","author":"Wang","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118764_bb0285","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejmech.2012.10.005","article-title":"Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element","volume":"58","author":"Pandya","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0290","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct factor xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bmc.2026.118764_bb0295","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4065\/82.7.864","article-title":"How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults","volume":"82","author":"Kamal","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.bmc.2026.118764_bb0300","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based Design of Novel Potent Nonpeptide Thrombin Inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118764_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118764_bb0310","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118764_bb0315","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/dmd.113.053561","article-title":"Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers","volume":"42","author":"Ishiguro","year":"2014","journal-title":"Drug Met Dispos"},{"key":"10.1016\/j.bmc.2026.118764_bb0320","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0049-3848(79)90064-1","article-title":"Bleeding time in laboratory animals. II- a comparison of different assay conditions in rats","volume":"15","author":"Dejana","year":"1979","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.bmc.2026.118764_bb0325","first-page":"1998","article-title":"Design, synthesis, pharmacological evaluation and molecular docking studies of substituted Oxadiazolyl-2-Oxoindolinylidene propane hydrazide derivatives","volume":"27","author":"Kerzare","year":"2016","journal-title":"J Braz Chem Soc"},{"key":"10.1016\/j.bmc.2026.118764_bb0330","article-title":"Rutin from Begonia roxburghii modulates iNOS and Sep a activity in treatment of Shigella flexneri induced diarrhoea in rats: an in vivo and computational analysis","volume":"184","author":"Prasad","year":"2013","journal-title":"Micro Pathogen"},{"key":"10.1016\/j.bmc.2026.118764_bb0335","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/ci100436p","article-title":"FRED pose prediction and virtual screening accuracy","volume":"51","author":"McGann","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118764_bb0340","series-title":"AMBER","author":"Case","year":"2018"},{"key":"10.1016\/j.bmc.2026.118764_bb0345","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/ct400314y","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald","volume":"9","author":"Salomon-Ferrer","year":"2013","journal-title":"J Chem Theor Comput"},{"issue":"14","key":"10.1016\/j.bmc.2026.118764_bb0350","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1021\/ja0759141","article-title":"Quantum mechanical\/molecular mechanical simulation study of the mechanism of hairpin ribozyme catalysis","volume":"130","author":"Nam","year":"2008","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/j.bmc.2026.118764_bb0355","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J Chem Theor Comput."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:36:51Z","timestamp":1788597411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":71,"alternative-id":["S0968089626002208"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118764","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel furo[2,3-d]pyrimidinones as direct thrombin inhibitors: Design, synthesis and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118764"}}